1. Academic Validation
  2. Let-7b regulates the adriamycin resistance of chronic myelogenous leukemia by targeting AURKB in K562/ADM cells

Let-7b regulates the adriamycin resistance of chronic myelogenous leukemia by targeting AURKB in K562/ADM cells

  • Leuk Lymphoma. 2020 Dec;61(14):3451-3459. doi: 10.1080/10428194.2020.1811269.
Xue Zhou 1 Xiancheng Ma 1 Hang Sun 2 Xue Li 1 Huizhen Cao 1 Youzhang Jiang 1 Pingyu Wang 2 Shuyang Xie 2 Youjie Li 2 Yunxiao Sun 1
Affiliations

Affiliations

  • 1 Department of Pediatrics, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, China.
  • 2 Key Laboratory of Tumor Molecular Biology, Department of Biochemistry and Molecular Biology, Binzhou Medical University, Yantai, China.
Abstract

Chronic myeloid leukemia (CML) is a malignant hematological disease, and drug resistance is often related to poor prognosis. MicroRNAs (miRNA) play a pivotal role in transcriptional regulation, cell development, and chemotherapy resistance. Here, we describe the effect of let-7b on resistant leukemia cells and examine the relevance of let-7b as a biomarker for adriamycin resistance. Results showed that let-7b was downregulated in K562/ADM (KA) cells, and the downregulation of let-7b in K562 and KA cells increased ADM resistance. The inhibition of let-7b subsequently induced the upregulation of AURKB. Finally, results proved that the PI3K/Akt/ERK pathway was related to AURKB-activated resistance. Our research indicated that the underexpression of let-7b and overexpression of AURKB contributed to the resistance of CML, and its function is partly regulated by the PI3K/Akt/ERK pathway. Thus, our further understand of its inhibitory effect may promise a new therapeutic strategy to overcome chemotherapeutic resistance in CML.

Keywords

AURKB; Chronic myelogenous leukemia; adriamycin resistance; let-7b.

Figures
Products